Clinical Trial Update: A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing sapanisertib alone or in combination with MLN1117 or paclitaxel in women with endometrial neoplasms has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms

Drugs mentioned

• MLN1117 (MLN1117)
• PACLITAXEL (PACLITAXEL)
• Sapanisertib (sapanisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Endometrial Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-06-09